-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$92.40180% Upside
Structure Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Structure Therapeutics Inc.?
Structure Therapeutics Inc. has been rated by research analysts at Morgan Stanley, Piper Sandler, JMP Securities, BMO Capital, Cantor Fitzgerald in the past 90 days.